New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 4, 2012
06:38 EDTJAZZCorrection: Jazz Pharmaceuticals initiates Erwinaze trial, says Brean Capital
Jazz announced initiated its new clinical trial for Erwinaze with will evaluate intravenous administration in patients with ALL as an alternative to intramuscular injection. Brean Murray maintains its estimates but believes there could be upside to its 2014 forecast. Shares are Buy rated with an $81 price target.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
14:42 EDTJAZZJazz Pharmaceuticals management to meet with Canaccord
Group dinner to be held in New York on November 30 hosted by Canaccord.
07:33 EDTJAZZMylan launches Clozapine Orally Disintegrating Tablets in the U.S.
Mylan (MYL) announced the U.S. launch of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical's FazaClo (JAZZ). Mylan received final approval from the FDA for its Abbreviated New Drug Application, or ANDA, for this product, which is used for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment.
November 18, 2015
08:28 EDTJAZZLeerink to hold a bus tour
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use